Pembrolizumab was associated with an overall objective response rate of 33%, 12-month progression-free survival rate of 35%, and median overall survival of 23 months among patients with advanced melanoma, according to a study by Antoni Ribas and colleagues published in JAMA.
An expert critique published in the online ASCO Reading Room comments upon a study showing that lower vitamin D levels in melanoma patients were associated with poorer outcomes.
Pembrolizumab has demonstrated therapeutic activity in brain metastases of patients with melanoma (and non-small cell lung cancer), according to early results of an ongoing randomized phase 2 trial.
A recent study explores the relationship between sunscreen use and lifestyle factors associated with mortality and morbidity among young adults. Lifestyle factors examined included physical activity, substance abuse, smoking, sexual behavior, unintentional injury, and mental well-being
In a recent letter to the editor in the New England Journal of Medicine, researchers reported two cases of demyelinating polyradiculoneuropathy after treatment with pembrolizumab (Keytruda) for advanced melanoma.
As of 1 September 2016 oncologists will be able to offer pembrolizumab (Keytruda) to patients with unresectable or metastatic melanoma, subject to the same clinical criteria as nivolumab (Opdivo).
In its most recent review of the topic, the US Preventive Services Task Force (USPSTF) concludes that the current evidence is insufficient to assess the balance of benefits and harms of visual skin examination by a clinician to screen for skin cancer in adults.
The inaugural Locoregional Melanoma 2016 conference | Multidisciplinary Management of Locoregionally Advanced Melanoma – from Surgery to Immunotherapy will be held in Melbourne on 26-27 August 2016.
A questionnaire used in monitoring sun-related behavior is “the first validated tool to measure UV exposure in a national population-based sample”, according to authors of a Danish study.
Digital dermoscopy follow-up is a valid management strategy for patients with multiple atypical nevi, according to authors of a recent study.